Wall Street Zen Downgrades Pyxis Oncology (NASDAQ:PYXS) to Sell

Key Points

• Wall Street Zen downgraded Pyxis Oncology (NASDAQ:PYXS) from a "hold" to a "sell" in a research note issued Sunday.
• Analyst views are mixed—five Buys, one Hold and one Sell—yielding an average rating of Moderate Buy with an average target of $7.00, while the stock trades around $1.48 (1‑year range $0.83–$5.55).
• Pyxis beat quarterly expectations with an EPS loss of ($0.29) versus a ($0.35) estimate and revenue of $11.04M (vs. $0.13M est.), but remains unprofitable and analysts forecast a full‑year EPS of −1.04.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued on Sunday.

A number of other research firms have also issued reports on PYXS. Weiss Ratings reissued a "sell (d-)" rating on shares of Pyxis Oncology in a research report on Thursday, January 22nd. HC Wainwright reiterated a "buy" rating and set a $7.00 target price on shares of Pyxis Oncology in a research report on Tuesday, March 24th. Stifel Nicolaus reduced their target price on Pyxis Oncology from $9.00 to $8.00 and set a "buy" rating for the company in a report on Tuesday, March 24th. Finally, Royal Bank Of Canada reduced their target price on shares of Pyxis Oncology from $8.00 to $5.00 and set an "outperform" rating for the company in a research report on Thursday, December 18th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $7.00.

Pyxis Oncology Price Performance

Shares of Pyxis Oncology stock opened at $1.48 on Friday. The stock has a market capitalization of $92.99 million, a PE ratio of -1.15 and a beta of 1.41. Pyxis Oncology has a 1-year low of $0.83 and a 1-year high of $5.55. The company's fifty day simple moving average is $1.46 and its 200-day simple moving average is $2.48.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last announced its earnings results on Monday, March 23rd. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.06. The company had revenue of $11.04 million for the quarter, compared to the consensus estimate of $0.13 million. As a group, research analysts anticipate that Pyxis Oncology will post -1.04 EPS for the current year.

Institutional Investors Weigh In On Pyxis Oncology

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of America Corp DE lifted its position in Pyxis Oncology by 20.3% during the 4th quarter. Bank of America Corp DE now owns 53,745 shares of the company's stock worth $84,000 after acquiring an additional 9,062 shares during the period. Acadian Asset Management LLC purchased a new position in shares of Pyxis Oncology during the 1st quarter worth approximately $81,000. XTX Topco Ltd purchased a new stake in shares of Pyxis Oncology in the second quarter valued at $40,000. Marshall Wace LLP purchased a new position in Pyxis Oncology in the 2nd quarter valued at about $163,000. Finally, Qube Research & Technologies Ltd lifted its stake in shares of Pyxis Oncology by 128.4% during the second quarter. Qube Research & Technologies Ltd now owns 103,063 shares of the company's stock valued at $113,000 after buying an additional 57,935 shares during the period. Institutional investors and hedge funds own 39.07% of the company's stock.

About Pyxis Oncology

Pyxis Oncology NASDAQ: PYXS is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company's platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.